Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2025)

Indivior Pharmaceuticals has reported Total Debt over the past 5 years, most recently at $319.0 million for Q4 2025.

  • Quarterly results put Total Debt at $319.0 million for Q4 2025, down 4.2% from a year ago — trailing twelve months through Dec 2025 was $319.0 million (down 4.2% YoY), and the annual figure for FY2025 was $319.0 million, down 4.2%.
  • Total Debt for Q4 2025 was $319.0 million at Indivior Pharmaceuticals, down from $322.0 million in the prior quarter.
  • Over the last five years, Total Debt for INDV hit a ceiling of $333.0 million in Q4 2024 and a floor of $240.0 million in Q4 2022.
  • Median Total Debt over the past 5 years was $320.5 million (2025), compared with a mean of $293.9 million.
  • Biggest five-year swings in Total Debt: surged 38.75% in 2024 and later dropped 4.2% in 2025.
  • Indivior Pharmaceuticals' Total Debt stood at $242.0 million in 2021, then decreased by 0.83% to $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then surged by 38.75% to $333.0 million in 2024, then fell by 4.2% to $319.0 million in 2025.
  • The last three reported values for Total Debt were $319.0 million (Q4 2025), $322.0 million (Q3 2025), and $326.0 million (Q2 2025) per Business Quant data.